Welcome to the OBR Oncology Pipeline Online™

We strive to provide the most comprehensive and up to date oncology pipeline information resource that is widely available on the web. Explore the current state of the entire oncology pipeline by selecting a tumor type below. Alternatively, select one of the tabs below to search by category or use the main search box to customize your own search. Send us your feedback at editor@oncbiz.com.

Disclaimer: This is an informational database only. Having a product listed in this database in no way implies that the associated company or organization endorses or recommends the use of that product in development. For further information, we recommend contacting the associated company directly.

Furthermore, the information contained in this database was compiled directly from each company's website as well as through additional resources available on the web. While we attempt to ensure the accuracy of this database, the information provided is only as accurate as each company provides and makes available to the general public. We thank you for your understanding.

A number of companies are following in Dendreon's footsteps with personalized cancer vaccines in their pipelines.

Catch up on a recent Scientific American post providing an overview of this newer class of cancer therapies. Then dig deeper on the companies and cancer vaccines being developed for tumor types including metastatic melanoma, two different kinds of lymphoma, and Glioblastoma multiforme (GBM).

Read about Bristol-Myers Squibb's ipilimumab; Northwest Biotherapeutics' DCVax®; and Biovest's BiovaxID®. In addition there's a Bloomberg update on Merck KGaA's cancer vaccines Stimuvax® and VXM01.

Recent Oncology Pipeline News

Celldex Says Pfizer Ends Cancer Vaccine Deal; Shares Fall

(Reuters) September 3, 2010 - Celldex Therapeutics Inc said its partner Pfizer ended the deal to co-develop Celldex's cancer vaccine, its lead product, as the program was no longer a strategic priority for the drug giant.
read article »

Celgene Seeks to Stop Natco's Generic Revlimid

(Reuters) September 3, 2010 - Celgene Corp said it plans to file a complaint alleging infringement against India's Natco Pharma Ltd, which has submitted a request to the U.S. Food and Drug Administration for authorization to make and sell generic versions of Celgene's cancer drug Revlimid in the United States.
read article »

Read ALL News »

Clinical Trial Resource Window

Progression-free survival, or PFS, remains a contentious surrogate endpoint in oncology clinical trials according to a July 27th NCI Cancer Bulletin featured article on Avastin.

Recently an ODAC committee voted 12 to 1 against the drug's use in combination with chemotherapy as a first-line treatment for advanced breast cancer. Whether the FDA will decide to rescind bevacizumab's approval as a breast cancer treatment remains up in the air until this September 2010.

Read about the original trial that Avastin's accelerated approval was based on, get more information on two pivotal follow-up studies, plus Dr. Richard Pazdur, director of the FDA’s Office of Oncology Drug Products, offers his commentary here.

Stay ahead of market moving oncology events and peer into the future of the oncology industry with the new OBR Radar.